Roth adjusts DelMar Pharma price target to $12

Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday.

Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a senior exchange, either NASDAQ or NYSE-MKT, shortly.

He said that following a preferred share financing to fund operations through the end of 2017, DelMar is now focused on two primary events: providing visibility from FDA discussions shortly on the pivotal path forward for VAL-083 in recurrent glioblastoma and initiating a Phase 3 study in post-Avastin recurrent glioblastoma in late 2016.

VAL-083 is also expected to expand into two new Phase 2 studies in 2016, including first recurrence glioblastoma in collaboration with MD Anderson and front-line glioblastoma in MGMT (O6-methylguanine–DNA methyltransferase)-positive patients.

Mr. Pantginis said the company envisions a “new paradigm” where VAL-083 could address two-thirds of the glioblastoma multiforme population, where the standard Temodar would be ineffective due to MGMT status and where patients have failed Temodar.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.